Abstract 326P
Background
Indocyanine green (ICG) has the potential to improve sentinel lymph node (SLN) mapping. This current cohort study was designed to assess the value of ICG using a new ICG handheld system with radioisotope (RI) in patients with early breast cancer undergoing SLN biopsy.
Methods
A prospective self-controlled trial compared the detection efficacies of ICG and RI was conducted. Concordance (ICG and RI-positive cases divided by RI-positive cases) and reverse concordance (ICG and RI-positive cases divided by ICG-positive cases) were documented and adverse event were also assessed.
Results
Of 69 patients (median age 56.7 (range 33-85), median BMI 22.6 (range 17.0 – 44.5)) enrolled between 2019 and 2021, 71 SLN biopsies were performed. Sixty-one (85.9%) underwent upfront surgery, while ten (14.1%) were given neoadjuvant treatment. Thirty-four breast-conserving surgeries (BCS) (47.9%), 33 mastectomies (46.5%) and four cryotherapies (5.6%) were performed. No adverse event nor skin staining were reported. The SLN identification rate was 87.3% (62/71) for ICG and 95.8% (68/71) for RI (p=0.13). Dual tracer method resulted in 97.2% successful identification, significantly superior to ICG alone (p=0.04, OR 5.0, CI 1.0-24.1) and and was in line with the reported rate of 96.7% (94.3-99.1)1 by blue dye and RI. Concordance and reverse concordance rates were 89.7% and 98.4%, respectively. A median of 2 lymph nodes was detected by both ICG (range 0 – 6) and IR (range 0 – 5) with no statistical difference (p=0.60). Of 10 cases with 13 metastatic nodes confirmed by histology, both ICG and RI achieved 100% concordance rates. Breast conserving treatments had a higher ICG failure rate compared to mastectomy (21.1% vs 3.0%, p=0.05, OR 8.5, CI 1.0-72.4). In addition, among three cases with prior surgery, two failed ICG SLN identification. Meanwhile, age, BMI, tumour location, multifocality, neoadjuvant treatment, and ICG volume showed no significant correlation with ICG detection rate.
Conclusions
The combined use of ICG and RI ensures adequate SLN identification without problems known with the use of blue dye, such as skin staining and anaphylaxis. A higher failure rate was noted in patients with breast-conserving treatments for ICG tracing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02
283P - Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Presenter: Michelino De Laurentiis
Session: Poster session 02
284P - Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Presenter: Vanessa Wieder
Session: Poster session 02
285P - Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Presenter: Stefania Morganti
Session: Poster session 02
286P - Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Presenter: Antonino Musolino
Session: Poster session 02
287P - Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
Presenter: Johan Staaf
Session: Poster session 02
288P - Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience
Presenter: Alper Türkel
Session: Poster session 02
289P - Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Presenter: Andrea Vethencourt
Session: Poster session 02
290P - Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Presenter: Alessandra Gennari
Session: Poster session 02
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02